<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36948977</PMID><DateCompleted><Year>2023</Year><Month>05</Month><Day>29</Day></DateCompleted><DateRevised><Year>2023</Year><Month>08</Month><Day>11</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1879-0828</ISSN><JournalIssue CitedMedium="Internet"><Volume>112</Volume><PubDate><Year>2023</Year><Month>Jun</Month></PubDate></JournalIssue><Title>European journal of internal medicine</Title><ISOAbbreviation>Eur J Intern Med</ISOAbbreviation></Journal><ArticleTitle>Association between cumulative dose of hydroxychloroquine and electrocardiographic abnormalities in patients with systemic lupus erythematosus.</ArticleTitle><Pagination><StartPage>70</StartPage><EndPage>76</EndPage><MedlinePgn>70-76</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ejim.2023.03.014</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0953-6205(23)00086-9</ELocationID><Abstract><AbstractText Label="OBJECTIVE">Hydroxychloroquine (HCQ) is one of the most used drugs in patients with systemic lupus erythematosus (SLE). In these patients, where heart involvement is common, cardiac HCQ toxicity may lead to fatal outcomes. The aim of this work is to study the influence of cumulative HCQ (cHCQ) in a selected group of patients with SLE and its association with electrocardiographic (EKG) abnormalities.</AbstractText><AbstractText Label="METHODS">Single-center retrospective, observational study in which data were collected from the medical records of consecutive patients with a diagnosis of SLE who started treatment with HCQ and who had a 12-lead EKG before starting treatment and during follow-up. EKG abnormalities were grouped as conduction or structural abnormalities. The association of cHCQ with the occurrence of EKG disturbances was analyzed together with other demographic and clinical variables through univariate and multivariate logistic regression models.</AbstractText><AbstractText Label="RESULTS">105 patients were selected with median cHCQ of 913 g. The sample was classified into two groups, above or below 913 g. Significantly, more conduction disturbances were observed in the group above the median (OR: 2.89; 95%CI: 1.01-8.23). In the multivariate analysis, the OR per 100&#xa0;g of cHCQ dose was 1.06 (95%CI: 0.99-1.14). Age was the only variable associated with conduction disturbances. There were no significant differences in the development of structural abnormalities and a tendency for more high-grade atrioventricular block was shown.</AbstractText><AbstractText Label="CONCLUSION">Our study suggests an association between the cHCQ and the development of EKG conduction disturbances that disappears after multivariate adjustment. No increased number of structural abnormalities was observed.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023. Published by Elsevier B.V.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zubiaur</LastName><ForeName>Jon</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Cardiology, Hospital Universitario Marqu&#xe9;s de Valdecilla, IDIVAL, University of Cantabria, Santander, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Herrero-Morant</LastName><ForeName>Alba</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Rheumatology, Hospital Universitario Marqu&#xe9;s de Valdecilla, IDIVAL, University of Cantabria, Avda. Valdecilla s/n., ES, Santander 39008, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Margarida de Castro</LastName><ForeName>Adri&#xe1;n</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Cardiology, Hospital Universitario Marqu&#xe9;s de Valdecilla, IDIVAL, University of Cantabria, Santander, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>P&#xe9;rez-Barqu&#xed;n</LastName><ForeName>Raquel</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Cardiology, Hospital Universitario Marqu&#xe9;s de Valdecilla, IDIVAL, University of Cantabria, Santander, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ferraz-Amaro</LastName><ForeName>Ivan</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Rheumatology, Hospital Universitario de Canarias, La Laguna, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Loricera</LastName><ForeName>Javier</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Rheumatology, Hospital Universitario Marqu&#xe9;s de Valdecilla, IDIVAL, University of Cantabria, Avda. Valdecilla s/n., ES, Santander 39008, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Casta&#xf1;eda</LastName><ForeName>Santos</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Rheumatology, Hospital Universitario de La Princesa and IIS-IPrincesa, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blanco</LastName><ForeName>Ricardo</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Rheumatology, Hospital Universitario Marqu&#xe9;s de Valdecilla, IDIVAL, University of Cantabria, Avda. Valdecilla s/n., ES, Santander 39008, Spain. Electronic address: rblancovela@gmail.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D064888">Observational Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>03</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Eur J Intern Med</MedlineTA><NlmUniqueID>9003220</NlmUniqueID><ISSNLinking>0953-6205</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>4QWG6N8QKH</RegistryNumber><NameOfSubstance UI="D006886">Hydroxychloroquine</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018501">Antirheumatic Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006886" MajorTopicYN="N">Hydroxychloroquine</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018501" MajorTopicYN="Y">Antirheumatic Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015999" MajorTopicYN="N">Multivariate Analysis</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Cardiac conduction disturbances</Keyword><Keyword MajorTopicYN="N">Electrocardiogram</Keyword><Keyword MajorTopicYN="N">Hydroxychloroquine</Keyword><Keyword MajorTopicYN="N">Systemic lupus erythematosus</Keyword></KeywordList><CoiStatement>Declaration of Competing Interest Disclosures that may be interpreted as constituting of possible conflict(s) of interest for this study: Dr. Iv&#xe1;n Ferraz-Amaro would like to acknowledge that he has received grants/research supports from Abbott, MSD, Janssen, and Roche, as well as consultation fees from company sponsored speakers bureaus associated with Abbott, Pfizer, Roche, Sanofi, Celgene, and MSD.&#xa0;J. Loricera has consultation fees/participation in company-sponsored speaker&#xb4;s bureau from Roche, Novartis, UCB Pharma, MSD, Celgene, and Gr&#xfc;nenthal and has received support for attending meetings and/or travel from Janssen, Abbvie, Roche, Novartis, MSD, UCB Pharma, Celgene, Lilly, Pfizer, Gal&#xe1;pagos. S. Casta&#xf1;eda has received consultation fees in company sponsored speaker's bureau from Amgen, Bristol-Myers-Squibb, Gr&#xfc;nenthal Pharma, Janssen, Eli Lilly, MSD, Novartis, Sanofi, Sobi, Stata and UCB, and also has received grants/research support from MSD and Pfizer. S. Casta&#xf1;eda is also assistant professor of the c&#xe1;tedra UAM-Roche, EPID-Future, Universidad Aut&#xf3;noma de Madrid (UAM), Madrid, Spain. R. Blanco has consultation fees/participation in company-sponsored speaker&#xb4;s bureau from Abbvie, Lilly, Pfizer, Roche, BMS, Janssen and MSD, and have received grants/research supports from Abbvie, MSD, and Roche. The rest of the authors do not declare having conflicts of interest related to this work.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>1</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>3</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>3</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>5</Month><Day>29</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>3</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>3</Month><Day>22</Day><Hour>23</Hour><Minute>12</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36948977</ArticleId><ArticleId IdType="doi">10.1016/j.ejim.2023.03.014</ArticleId><ArticleId IdType="pii">S0953-6205(23)00086-9</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>